Scott Cruickshank

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · The Lancet Oncology · 2018 · 552 citations · Full text

Medicine, Molecular Biology, Oncology +16

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Denise A. Yardley, Roohi Ismail‐Khan, Bohuslav Melichar et al. · Journal of Clinical Oncology · 2013 · 418 citations

Medicine, Oncology, Pharmacology +17

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James M. Schuster, R. K. Lai, Lawrence D. Recht et al. · Neuro-Oncology · 2015 · 417 citations · Full text

Medicine, Oncology, Pharmacology +17

‘Chemobrain’ in breast carcinoma?

Jeffrey S. Wefel, Renato Lenzi, Richard L. Theriault et al. · Cancer · 2004 · 335 citations

Medicine, Oncology, Psychology +13